M. V. Larina, Yu. P. Finashutina, N. A. Kravchuk, V. A. Misyurin, V. N. Novoseletsky, D. S. Balabashin, O. N. Solopova, D. V. Sokolova, V. S. Pokrovsky, D. A. Dolgikh, T. K. Aliev, A. V. Misyurin, M. P. Kirpichnikov
{"title":"癌睾丸抗原PRAME人源化抗体抗增殖活性的研究","authors":"M. V. Larina, Yu. P. Finashutina, N. A. Kravchuk, V. A. Misyurin, V. N. Novoseletsky, D. S. Balabashin, O. N. Solopova, D. V. Sokolova, V. S. Pokrovsky, D. A. Dolgikh, T. K. Aliev, A. V. Misyurin, M. P. Kirpichnikov","doi":"10.1134/S1068162025603799","DOIUrl":null,"url":null,"abstract":"<p><b>Objective:</b> The PRAME antigen (Preferentially Expressed Antigen in Melanoma), a cancer-testis antigen expressed in various tumor types, represents an attractive target for targeted cancer therapy. <b>Methods:</b> A humanized antibody (6H8Hu) was developed based on the monoclonal antibody 6H8 specific to the PRAME protein. The antibody was produced in CHO cells. Results and Discussion: The humanized antibody retains the high affinity of the parental mAb to the antigen (1.2 nM), binds to both recombinant and native PRAME protein, inhibits the proliferation of the PRAME-positive human melanoma cell line Mel Ibr, and suppresses tumor nodule growth <i>in vivo</i> to a degree comparable to that of the murine antibody 6H8 and the cytostatic agent melphalan. <b>Conclusions:</b> The humanized antibody 6H8Hu is a promising candidate for targeted therapy against PRAME-positive melanoma, showing potential comparable to murine antibodies and conventional cytotoxic treatments.</p>","PeriodicalId":758,"journal":{"name":"Russian Journal of Bioorganic Chemistry","volume":"51 5","pages":"2089 - 2099"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Study of the Antiproliferative Activity of a Humanized Antibody to the Cancer-Testis Antigen PRAME\",\"authors\":\"M. V. Larina, Yu. P. Finashutina, N. A. Kravchuk, V. A. Misyurin, V. N. Novoseletsky, D. S. Balabashin, O. N. Solopova, D. V. Sokolova, V. S. Pokrovsky, D. A. Dolgikh, T. K. Aliev, A. V. Misyurin, M. P. Kirpichnikov\",\"doi\":\"10.1134/S1068162025603799\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><b>Objective:</b> The PRAME antigen (Preferentially Expressed Antigen in Melanoma), a cancer-testis antigen expressed in various tumor types, represents an attractive target for targeted cancer therapy. <b>Methods:</b> A humanized antibody (6H8Hu) was developed based on the monoclonal antibody 6H8 specific to the PRAME protein. The antibody was produced in CHO cells. Results and Discussion: The humanized antibody retains the high affinity of the parental mAb to the antigen (1.2 nM), binds to both recombinant and native PRAME protein, inhibits the proliferation of the PRAME-positive human melanoma cell line Mel Ibr, and suppresses tumor nodule growth <i>in vivo</i> to a degree comparable to that of the murine antibody 6H8 and the cytostatic agent melphalan. <b>Conclusions:</b> The humanized antibody 6H8Hu is a promising candidate for targeted therapy against PRAME-positive melanoma, showing potential comparable to murine antibodies and conventional cytotoxic treatments.</p>\",\"PeriodicalId\":758,\"journal\":{\"name\":\"Russian Journal of Bioorganic Chemistry\",\"volume\":\"51 5\",\"pages\":\"2089 - 2099\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-09-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Russian Journal of Bioorganic Chemistry\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://link.springer.com/article/10.1134/S1068162025603799\",\"RegionNum\":4,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Bioorganic Chemistry","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1134/S1068162025603799","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Study of the Antiproliferative Activity of a Humanized Antibody to the Cancer-Testis Antigen PRAME
Objective: The PRAME antigen (Preferentially Expressed Antigen in Melanoma), a cancer-testis antigen expressed in various tumor types, represents an attractive target for targeted cancer therapy. Methods: A humanized antibody (6H8Hu) was developed based on the monoclonal antibody 6H8 specific to the PRAME protein. The antibody was produced in CHO cells. Results and Discussion: The humanized antibody retains the high affinity of the parental mAb to the antigen (1.2 nM), binds to both recombinant and native PRAME protein, inhibits the proliferation of the PRAME-positive human melanoma cell line Mel Ibr, and suppresses tumor nodule growth in vivo to a degree comparable to that of the murine antibody 6H8 and the cytostatic agent melphalan. Conclusions: The humanized antibody 6H8Hu is a promising candidate for targeted therapy against PRAME-positive melanoma, showing potential comparable to murine antibodies and conventional cytotoxic treatments.
期刊介绍：
Russian Journal of Bioorganic Chemistry publishes reviews and original experimental and theoretical studies on the structure, function, structure–activity relationships, and synthesis of biopolymers, such as proteins, nucleic acids, polysaccharides, mixed biopolymers, and their complexes, and low-molecular-weight biologically active compounds (peptides, sugars, lipids, antibiotics, etc.). The journal also covers selected aspects of neuro- and immunochemistry, biotechnology, and ecology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
